Isotretinoin versus weekly pulse dose azithromycin in the treatment of acne- A comparative study

Journal of Pakistan Association of Dermatologists

Volumn 18, Issue 1, 2008, Pages 9-14

  Wahab, Md Abdul ^a   Rahman, M Hasibur ^a,b   Monamie, Nasrin Sultana ^a,c   Jamaluddin, Mohammad ^a   Khondker, Lubna ^a   Afroz, Wahida ^a,d  

^a BANGABANDHU SHEIKH MUJIB MEDICAL UNIVERSITY   (Bangladesh)

^b Department of Biochemistry   (Bangladesh)

^c BIHS   (Bangladesh)

^d Bangladesh rhriaz29 gmailcom https: orcidorg 0000 0003 4162 9545   (Bangladesh)

Author keywords

Acne; Azithromycin; Isotretinoin

Indexed keywords

ADAPALENE; AZITHROMYCIN; ERYTHROMYCIN; ISOTRETINOIN;

ABDOMINAL DISCOMFORT; ACNE; ADJUVANT THERAPY; ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; FACE DISORDER; FEMALE; HUMAN; LIP DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NAUSEA; PAKISTAN; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; XEROSIS;

EID: 77950814682     PISSN: 15609014     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Anis LA, Gaspari AA. Cutaneous reactions to recombinant cytokine therapy. J Am Acad Dermatol 1995; 33: 393-410.
2. Koshy A, Marcellin P, Martinot M, Madda JP. Improved response to ribavirin interferon combination compared with interferon alone in patients with type 4 chronic hepatitis C without cirrhosis. Liver 2000; 20: 335-9. (Pubitemid 30488004)
3. Lau J. Mechanism of action of ribavirin in the combination treatment of chronic HCV. J Hepatology 2002; 35: **. (Pubitemid 34453997)
4. Besiss D, Luong MS, Blanc P et al. Straight hair associated with interferon plus ribavirin in hepatitis C infection. Br J Dermatol 2002; 147: 392-3.
5. Hernandez-Nunez A, Fernandez-Herrera J, Buceta LR, Garcia-Diez A. Trichomegaly with interferon alpha-2b. Lancet 2002; 30:359(9312):1107.
6. Howaizi M. Pegylated interferon-induced eyelid and eyebrow trichomegaly during chronic hepatitis C. J Gastroenterol Hepatol 2005; 20: 1945-6. (Pubitemid 43961059)
7. Baccard M, Morel P. Excessive growth of eyelashes in patients with acquired immunodeficiency syndrome. Cutis 1994; 53: 83-4. (Pubitemid 24127358)
8. Javamanne DG, Davan MR, Porter R. Cyclosporin-induced trichomegaly of accessory lashes as a cause of ocular irritation. Nephrol Dial Transplant 1996; 11: 1159-61. (Pubitemid 26182520)
9. Bouche O, Brixi-Benmansour H, Bertin A et al. Trichomegaly of the eyelashes following treatment with cetuximab. Ann Oncol 2005; 16: 1711-2. (Pubitemid 41510151)
10. Ward KM, Barnett C, Fox LP, Grossman ME. Eyelash trichomegaly associated with systemic tacrolimus. Arch Dermatol 2006; 142: 248. (Pubitemid 43276549)
11. Taliana G, Biliolli E, Cappanni M et al. Reversible alopecia universalis during treatment with PEG-interferon and ribavirin for chronic hepatitis C. J Chemother 2005; 17: 212-4. (Pubitemid 40732882)
12. Torres HA, Bull L, Arduino RC, Barnett BJ. Tongue hyperpigmentation in a Caucasian patient coinfected with HIV and Hepatitis C during peginterferon alfa-2b and ribavirin therapy. Am J Gastroenterol 2007; 102: 1334-5. (Pubitemid 46802016)
13. Willems M, Munte K, Den Hollander JC et al. Hyperpigmentation during interferon-alpha therapy for chronic hepatitis C virus infection. Br J Dermatol 2003; 149: 390-4. (Pubitemid 37100268)
14. Gurta C, Kauer C, Bergholz U et al. Tongue and skin hyperpigmentation during PEG-interferon-α/ribavirin therapy in dark-skinned non-caucasian patients with chronic hepatitis C. Am J Gastroenterol 2005; 100: 1-2. (Pubitemid 43381730)
15. Willems M, Munte K, Vrolijk JM et al. Hyperpigmentation during interferon-alpha therapy for chronic hepatitis C virus infection. Br J Dermatol 2003; 149: 390-4. (Pubitemid 37100268)
16. Sood A, Midha V, Bansal M et al. Lingual hyperpigmentation with pegylated interferon and ribavirin therapy in patients with chronic hepatitis C. Indian J Gastroenterol 2006; 25: 324. (Pubitemid 46708845)
17. Barreca T, Corsini G, Franceschini R et al. Lichen planus-induced by interferon-alpha-2a therapy for chronic active hepatitis C. Eur J Gastroenterol Hepatol 1995; 7: 367-8.
18. Protzer U, Ochsendorf FR, Leopolder-Ochsendorf A, Holtermuller KH. Exacerbation of lichen planus during interferon alfa-2a therapy for chronic active hepatitis C. Gastroenterology 1993; 104: 903-5. (Pubitemid 23059592)
19. Jauregui L, Garcia-patos V, Pedragosa R et al. Lichen planus associated with liver disease caused by hepatitis C virus. Gastroenterol Hepatol 1996; 19: 507-10.
20. Sanchez-Perez J, De Castro M, Buezo GF et al. Lichen planus and hepatitis C virus: prevalence and clinical presentation of patients with lichen planus and hepatitis C virus infection. Br J Dermatol 1996; 134: 715-9. (Pubitemid 26120741)
21. Bellman B, Reddy R, Falanga V. Generalized lichen planus associated with hepatitis C virus immunoreactivity. J Am Acad Dermatol 1996; 35: 770-2. (Pubitemid 26389481)
22. Schlesinger TE, Camisa C, Gay D, Bergfeld WF. Oral erosive lichen planus with epidermolytic hyperkeratosis during interferon alfa-2b therapy for chronic hepatitis C virus infection. J Am Acad Dermatol 1997; 36: 1023-5. (Pubitemid 27265924)
23. Lodi G, Giuliana M, Majorana A et al. Lichen planus and hepatitis C virus: a multicentre study of patients with oral lesions and a systematic review. Br J Dermatol 2004; 151: 1172-81. (Pubitemid 40030164)
24. Harden D, Skelton H, Smith KJ. Lichen planus associated with hepatitis C: no viral transcripts are found in the lichen planus, and effective therapy does not clear lichen planus. J Am Acad Dermatol 2003; 49: 847-52. (Pubitemid 37314872)
25. Sparsa A, Loustaud-Ratti V, Liozon E et al. Cutaneous reactions or necrosis from interferon alpha: can interferon be reintroduced after healing? Six case reports. Rev Med Interne 2000; 21: 756-63.
26. Sanders S, Busam K, Tahan SA et al. Granulomatous and suppurative dermatitis at interferon alfa injection sites: reports of 2 cases. J Am Acad Dermatol 2002; 46: 611-6.
27. Cogrel O, Doutre MS, Marliere V et al. Cutaneous sarcoidosis during interferon plus ribavirin treatment of hepatitis C virus: two cases. Br J Dermatol 2002; 146: 320-4. (Pubitemid 34264409)
28. Fischer J, Metzler G, Schaller M. Cosmetic permanent fillers for soft tissue augmentation. A new contraindication for interferon therapy. Arch Dermatol 2007; 143: 507-10. (Pubitemid 46631650)
29. Raison CL, Borisov AS, Broadwell SD et al. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry 2005; 66: 41-8.
30. Vignau J, Karlia L, Costisella O, Cannva V. Hepatitis C, and interferon a and depression: main physiopathlologic hypothesis. Encephale 2005; 31: 349-57.